Literature DB >> 11970991

A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo.

Janice M Kelly1, Kazuyoshi Takeda, Phillip K Darcy, Hideo Yagita, Mark J Smyth.   

Abstract

We have investigated the primary and secondary immunity generated in vivo by a MHC class I-deficient tumor cell line that expressed CD80 (B7-1). CD80 expression enhanced primary NK cell-mediated tumor rejection in vivo and T cell immunity against secondary tumor challenge. CD80 expression enhanced primary NK cell-mediated tumor rejection, and both NK cell perforin and IFN-gamma activity were critical for the rejection of MHC class I-deficient RMA-S-CD80 tumor cells. This primary rejection process stimulated the subsequent development of specific CTL and Th1 responses against Ags expressed by the MHC class I-deficient RMA-S tumor cells. The development of effective secondary T cell immunity could be elicited by irradiated RMA-S-CD80 tumor cells and was dependent upon NK cells and IFN-gamma in the priming response. Our findings demonstrate a key role for IFN-gamma in innate and adaptive immunity triggered by CD80 expression on tumor cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11970991     DOI: 10.4049/jimmunol.168.9.4472

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

Review 2.  Boosting vaccine efficacy the natural (killer) way.

Authors:  Carolyn E Rydyznski; Stephen N Waggoner
Journal:  Trends Immunol       Date:  2015-08-10       Impact factor: 16.687

Review 3.  The role of natural killer cells in tumor control--effectors and regulators of adaptive immunity.

Authors:  Morgan E Wallace; Mark J Smyth
Journal:  Springer Semin Immunopathol       Date:  2005-02-24

4.  Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.

Authors:  Kiran Kundu; Susmita Ghosh; Rhitajit Sarkar; Avishay Edri; Michael Brusilovsky; Orly Gershoni-Yahalom; Rami Yossef; Avishai Shemesh; Jean-Charles Soria; Vladimir Lazar; Ben-Zion Joshua; Kerry S Campbell; Moshe Elkabets; Angel Porgador
Journal:  Cancer Immunol Res       Date:  2019-06-04       Impact factor: 11.151

5.  NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors.

Authors:  Zusen Fan; Ping Yu; Yang Wang; Yugang Wang; May Lynne Fu; Wenhua Liu; Yonglian Sun; Yang-Xin Fu
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

6.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16

7.  Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses.

Authors:  Harlan P Jones; Yi-Chong Wang; Beau Aldridge; Jay M Weiss
Journal:  Cancer Immun       Date:  2008-02-19

8.  Natural killer cells modulate overt autoimmunity to homeostasis in nonobese diabetic mice after anti-CD3 F(ab')2 antibody treatment through secreting transforming growth factor-beta.

Authors:  Guojiang Chen; Gencheng Han; Jianan Wang; Renxi Wang; Ruonan Xu; Beifen Shen; Jiahua Qian; Yan Li
Journal:  Am J Pathol       Date:  2009-07-30       Impact factor: 4.307

9.  Defective expression and modulation of B7-2/CD86 on B cells in B cell chronic lymphocytic leukemia.

Authors:  Zhen-sheng Dai; Qin-fen Chen; Hong-zhou Lu; Yi Xie
Journal:  Int J Hematol       Date:  2009-05-09       Impact factor: 2.490

10.  Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase.

Authors:  Xiao-Lin Li; Marjolein Sluijter; Elien M Doorduijn; Shubha P Kale; Harris McFerrin; Yong-Yu Liu; Yan Li; Madhusoodanan Mottamal; Xin Yao; Fengkun Du; Baihan Gu; Kim Hoang; Yen H Nguyen; Nichelle Taylor; Chelsea R Stephens; Thorbald van Hall; Qian-Jin Zhang
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.